Axon Enterprise’s (AXON) Market Outperform Rating Reaffirmed at JMP Securities

Axon Enterprise (NASDAQ:AXON)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a note issued to investors on Monday,Benzinga reports. They currently have a $825.00 price objective on the biotechnology company’s stock. JMP Securities’ price objective would indicate a potential upside of 16.39% from the company’s current price.

Other equities analysts have also issued reports about the stock. Bank of America boosted their price target on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Zacks Research downgraded Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Wolfe Research began coverage on Axon Enterprise in a research note on Monday, July 7th. They issued an “outperform” rating on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. Finally, Raymond James Financial restated an “outperform” rating and set a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Stock Performance

AXON stock opened at $708.84 on Monday. Axon Enterprise has a 1 year low of $388.37 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The stock has a market capitalization of $55.64 billion, a price-to-earnings ratio of 175.02, a PEG ratio of 27.53 and a beta of 1.40. The stock’s fifty day moving average is $758.60 and its two-hundred day moving average is $703.76.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same period last year, the firm posted $1.20 earnings per share. The firm’s revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. On average, research analysts predict that Axon Enterprise will post 5.8 EPS for the current year.

Insider Transactions at Axon Enterprise

In other news, CFO Brittany Bagley sold 870 shares of Axon Enterprise stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $773.25, for a total transaction of $672,727.50. Following the sale, the chief financial officer owned 113,022 shares in the company, valued at $87,394,261.50. This trade represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $743.64, for a total value of $7,436,400.00. Following the completion of the sale, the chief executive officer directly owned 3,043,982 shares of the company’s stock, valued at $2,263,626,774.48. The trade was a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,932 shares of company stock worth $34,408,816. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors and hedge funds have recently modified their holdings of the business. Westside Investment Management Inc. increased its position in shares of Axon Enterprise by 4.8% during the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 13 shares during the last quarter. CVA Family Office LLC grew its stake in Axon Enterprise by 26.9% during the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock worth $55,000 after buying an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. raised its stake in Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 14 shares in the last quarter. Evergreen Capital Management LLC lifted its holdings in Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the period. Finally, LaSalle St. Investment Advisors LLC increased its stake in shares of Axon Enterprise by 2.1% during the first quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 16 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.